Yarrow Biotechnology Goes Public to Advance Targeted Antibodies for Graves Disease Treatment

Summary

Yarrow Biotechnology has entered the public markets following a merger to accelerate its anti-TSHR antibody pipeline. The firm aims to address unmet needs in Graves disease and Thyroid Eye Disease, conditions that disproportionately impact the female population.

Positioning inside the women's health category is being redrawn — the interesting question is which adjacent operators reprice. Look for follow-on moves from named investors, incumbents, and new entrants in the lane.

Sources

• OVUM Primary source